Cargando…

IODNE: An integrated optimization method for identifying the deregulated subnetwork for precision medicine in cancer

Subnetwork analysis can explore complex patterns of entire molecular pathways for the purpose of drug target identification. In this article, the gene expression profiles of a cohort of patients with breast cancer are integrated with protein‐protein interaction (PPI) networks using, simultaneously,...

Descripción completa

Detalles Bibliográficos
Autores principales: Mounika Inavolu, S, Renbarger, J, Radovich, M, Vasudevaraja, V, Kinnebrew, GH, Zhang, S, Cheng, L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351413/
https://www.ncbi.nlm.nih.gov/pubmed/28266149
http://dx.doi.org/10.1002/psp4.12167
_version_ 1782514774305669120
author Mounika Inavolu, S
Renbarger, J
Radovich, M
Vasudevaraja, V
Kinnebrew, GH
Zhang, S
Cheng, L
author_facet Mounika Inavolu, S
Renbarger, J
Radovich, M
Vasudevaraja, V
Kinnebrew, GH
Zhang, S
Cheng, L
author_sort Mounika Inavolu, S
collection PubMed
description Subnetwork analysis can explore complex patterns of entire molecular pathways for the purpose of drug target identification. In this article, the gene expression profiles of a cohort of patients with breast cancer are integrated with protein‐protein interaction (PPI) networks using, simultaneously, both edge scoring and node scoring. A novel optimization algorithm, integrated optimization method to identify deregulated subnetwork (IODNE), is developed to search for the optimal dysregulated subnetwork of the merged gene and protein network. IODNE is applied to select subnetworks for Luminal‐A breast cancer from The Cancer Genome Atlas (TCGA) data. A large fraction of cancer‐related genes and the well‐known clinical targets, ER1/PR and HER2, are found by IODNE. This validates the utility of IODNE. When applying IODNE to the triple‐negative breast cancer (TNBC) subtype data, we identified subnetworks that contain genes such as ERBB2, HRAS, PGR, CAD, POLE, and SLC2A1.
format Online
Article
Text
id pubmed-5351413
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-53514132017-03-22 IODNE: An integrated optimization method for identifying the deregulated subnetwork for precision medicine in cancer Mounika Inavolu, S Renbarger, J Radovich, M Vasudevaraja, V Kinnebrew, GH Zhang, S Cheng, L CPT Pharmacometrics Syst Pharmacol Original Articles Subnetwork analysis can explore complex patterns of entire molecular pathways for the purpose of drug target identification. In this article, the gene expression profiles of a cohort of patients with breast cancer are integrated with protein‐protein interaction (PPI) networks using, simultaneously, both edge scoring and node scoring. A novel optimization algorithm, integrated optimization method to identify deregulated subnetwork (IODNE), is developed to search for the optimal dysregulated subnetwork of the merged gene and protein network. IODNE is applied to select subnetworks for Luminal‐A breast cancer from The Cancer Genome Atlas (TCGA) data. A large fraction of cancer‐related genes and the well‐known clinical targets, ER1/PR and HER2, are found by IODNE. This validates the utility of IODNE. When applying IODNE to the triple‐negative breast cancer (TNBC) subtype data, we identified subnetworks that contain genes such as ERBB2, HRAS, PGR, CAD, POLE, and SLC2A1. John Wiley and Sons Inc. 2017-03-07 2017-03 /pmc/articles/PMC5351413/ /pubmed/28266149 http://dx.doi.org/10.1002/psp4.12167 Text en © 2017 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Mounika Inavolu, S
Renbarger, J
Radovich, M
Vasudevaraja, V
Kinnebrew, GH
Zhang, S
Cheng, L
IODNE: An integrated optimization method for identifying the deregulated subnetwork for precision medicine in cancer
title IODNE: An integrated optimization method for identifying the deregulated subnetwork for precision medicine in cancer
title_full IODNE: An integrated optimization method for identifying the deregulated subnetwork for precision medicine in cancer
title_fullStr IODNE: An integrated optimization method for identifying the deregulated subnetwork for precision medicine in cancer
title_full_unstemmed IODNE: An integrated optimization method for identifying the deregulated subnetwork for precision medicine in cancer
title_short IODNE: An integrated optimization method for identifying the deregulated subnetwork for precision medicine in cancer
title_sort iodne: an integrated optimization method for identifying the deregulated subnetwork for precision medicine in cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351413/
https://www.ncbi.nlm.nih.gov/pubmed/28266149
http://dx.doi.org/10.1002/psp4.12167
work_keys_str_mv AT mounikainavolus iodneanintegratedoptimizationmethodforidentifyingthederegulatedsubnetworkforprecisionmedicineincancer
AT renbargerj iodneanintegratedoptimizationmethodforidentifyingthederegulatedsubnetworkforprecisionmedicineincancer
AT radovichm iodneanintegratedoptimizationmethodforidentifyingthederegulatedsubnetworkforprecisionmedicineincancer
AT vasudevarajav iodneanintegratedoptimizationmethodforidentifyingthederegulatedsubnetworkforprecisionmedicineincancer
AT kinnebrewgh iodneanintegratedoptimizationmethodforidentifyingthederegulatedsubnetworkforprecisionmedicineincancer
AT zhangs iodneanintegratedoptimizationmethodforidentifyingthederegulatedsubnetworkforprecisionmedicineincancer
AT chengl iodneanintegratedoptimizationmethodforidentifyingthederegulatedsubnetworkforprecisionmedicineincancer